Mild to moderate Alzheimer dementia with insufficient neuropathological changes

Alberto Serrano-Pozo, Jing Qian, Sarah E. Monsell, Deborah Blacker, Teresa Gómez-Isla, Rebecca Betensky, John H. Growdon, Keith A. Johnson, Matthew P. Frosch, Reisa A. Sperling, Bradley T. Hyman

Research output: Contribution to journalArticle

Abstract

Recently, ∼16% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14% of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these "Aβ-negative" subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601

Original languageEnglish (US)
Pages (from-to)597-601
Number of pages5
JournalAnnals of Neurology
Volume75
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Alzheimer Disease
Amyloid
Positron-Emission Tomography
Neurofibrillary Tangles
Passive Immunization
Amyloid Plaques
Autopsy
Biomarkers
Databases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Serrano-Pozo, A., Qian, J., Monsell, S. E., Blacker, D., Gómez-Isla, T., Betensky, R., ... Hyman, B. T. (2014). Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Annals of Neurology, 75(4), 597-601. https://doi.org/10.1002/ana.24125

Mild to moderate Alzheimer dementia with insufficient neuropathological changes. / Serrano-Pozo, Alberto; Qian, Jing; Monsell, Sarah E.; Blacker, Deborah; Gómez-Isla, Teresa; Betensky, Rebecca; Growdon, John H.; Johnson, Keith A.; Frosch, Matthew P.; Sperling, Reisa A.; Hyman, Bradley T.

In: Annals of Neurology, Vol. 75, No. 4, 01.01.2014, p. 597-601.

Research output: Contribution to journalArticle

Serrano-Pozo, A, Qian, J, Monsell, SE, Blacker, D, Gómez-Isla, T, Betensky, R, Growdon, JH, Johnson, KA, Frosch, MP, Sperling, RA & Hyman, BT 2014, 'Mild to moderate Alzheimer dementia with insufficient neuropathological changes', Annals of Neurology, vol. 75, no. 4, pp. 597-601. https://doi.org/10.1002/ana.24125
Serrano-Pozo A, Qian J, Monsell SE, Blacker D, Gómez-Isla T, Betensky R et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Annals of Neurology. 2014 Jan 1;75(4):597-601. https://doi.org/10.1002/ana.24125
Serrano-Pozo, Alberto ; Qian, Jing ; Monsell, Sarah E. ; Blacker, Deborah ; Gómez-Isla, Teresa ; Betensky, Rebecca ; Growdon, John H. ; Johnson, Keith A. ; Frosch, Matthew P. ; Sperling, Reisa A. ; Hyman, Bradley T. / Mild to moderate Alzheimer dementia with insufficient neuropathological changes. In: Annals of Neurology. 2014 ; Vol. 75, No. 4. pp. 597-601.
@article{a0a7a5c231d340b9abe7f9c9a06e6a1b,
title = "Mild to moderate Alzheimer dementia with insufficient neuropathological changes",
abstract = "Recently, ∼16{\%} of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14{\%} of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these {"}Aβ-negative{"} subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601",
author = "Alberto Serrano-Pozo and Jing Qian and Monsell, {Sarah E.} and Deborah Blacker and Teresa G{\'o}mez-Isla and Rebecca Betensky and Growdon, {John H.} and Johnson, {Keith A.} and Frosch, {Matthew P.} and Sperling, {Reisa A.} and Hyman, {Bradley T.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/ana.24125",
language = "English (US)",
volume = "75",
pages = "597--601",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Mild to moderate Alzheimer dementia with insufficient neuropathological changes

AU - Serrano-Pozo, Alberto

AU - Qian, Jing

AU - Monsell, Sarah E.

AU - Blacker, Deborah

AU - Gómez-Isla, Teresa

AU - Betensky, Rebecca

AU - Growdon, John H.

AU - Johnson, Keith A.

AU - Frosch, Matthew P.

AU - Sperling, Reisa A.

AU - Hyman, Bradley T.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Recently, ∼16% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14% of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these "Aβ-negative" subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601

AB - Recently, ∼16% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14% of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these "Aβ-negative" subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601

UR - http://www.scopus.com/inward/record.url?scp=84899981521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899981521&partnerID=8YFLogxK

U2 - 10.1002/ana.24125

DO - 10.1002/ana.24125

M3 - Article

VL - 75

SP - 597

EP - 601

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -